Tiziana Life Sciences Ltd - Common Shares (NQ:TLSA)

1.295 +0.045 (+3.60%)

Streaming Delayed Price Updated: 1:41 PM EDT, Apr 6, 2026 Add to My Watchlist

Price and Volume

Volume	87,867
Open	1.230
Bid (Size)	1.290 (200)
Ask (Size)	1.300 (300)
Prev. Close	1.250
Today's Range	1.230 - 1.330
52wk Range	0.7301 - 2.600
Shares Outstanding	194,612,289
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging

April 01, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA

February 25, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Performance

YTD	-19.1%	-19.1%
1 Month	-6.8%	-6.8%
3 Month	-15.4%	-15.4%
6 Month	-34.3%	-34.3%
1 Year	+43.9%	+43.9%

More News

Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab

January 20, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Stock Rises On Advancing Second Asset Besides Foralumab: Retail Thinks Stock Has ‘So Much Potential’ ↗

September 25, 2025

Via Stocktwits

Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares

January 16, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million

January 16, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco

January 09, 2026

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA

December 29, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman

December 19, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences to Ring the Closing Bell at Nasdaq

December 17, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial

December 17, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

December 15, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering

December 15, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial

December 12, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

December 02, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

November 25, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

November 13, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Elon Musk Says Tesla, xAI Are 'Trending Towards Convergence' In Some Ways ↗

November 10, 2025

Via Benzinga

Aquestive Therapeutics Announces Leadership Expansion to Support Growth

November 04, 2025

From Aquestive Therapeutics, Inc.

Via GlobeNewswire

Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy

October 29, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

September 30, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody

September 25, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

September 24, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

September 15, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

September 09, 2025

From Tiziana Life Sciences Ltd.

Via GlobeNewswire

Frequently Asked Questions

Is Tiziana Life Sciences Ltd - Common Shares publicly traded?

Yes, Tiziana Life Sciences Ltd - Common Shares is publicly traded.

What exchange does Tiziana Life Sciences Ltd - Common Shares trade on?

Tiziana Life Sciences Ltd - Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Tiziana Life Sciences Ltd - Common Shares?

The ticker symbol for Tiziana Life Sciences Ltd - Common Shares is TLSA on the Nasdaq Stock Market

What is the current price of Tiziana Life Sciences Ltd - Common Shares?

The current price of Tiziana Life Sciences Ltd - Common Shares is 1.295

When was Tiziana Life Sciences Ltd - Common Shares last traded?

The last trade of Tiziana Life Sciences Ltd - Common Shares was at 04/06/26 01:41 PM ET

What is the market capitalization of Tiziana Life Sciences Ltd - Common Shares?

The market capitalization of Tiziana Life Sciences Ltd - Common Shares is 252.02M

How many shares of Tiziana Life Sciences Ltd - Common Shares are outstanding?

Tiziana Life Sciences Ltd - Common Shares has 252M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.